Marvin Slosman
Principal executive officer pay for Marvin Slosman, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
InspireMD, Inc. (NSPR) FY2022–FY2025
Aligned: paid up as stock roseCAP $115,272→$1,318,797 while $100 invested went $17.00→$207.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $696,809 | $115,272 |
| FY2023 | $3.2M | $5.9M |
| FY2024 | $3.3M | $2.4M |
| FY2025 | $3.1M | $1.3M |
The company's "$100 invested" index ran $17.00 at FY2022 → $207.00 by FY2025 — an annualized return of 130.1%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 130.1%/yr at NSPR ( FY2022–FY2025). See the CEO track-record ranking for context.